Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Identifying Novel Roles and the Therapeutic Potential of the Thrombin Receptor Protease Activated Receptor-1 (PAR1) in Lung Lymphatic Function and Acute Respiratory Distress Syndrome

Award Number: R01HL179084
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Identifying Novel Roles and the Therapeutic Potential of the Thrombin Receptor Protease Activated Receptor-1 (PAR1) in Lung Lymphatic Function and Acute Respiratory Distress Syndrome - Project Abstract Acute Respiratory Distress Syndrome (ARDS) is a devastating disease with high morbidity and mortality. The COVID-19 pandemic and the yearly toll of viral and bacterial pneumonia underscore the urgent need for a mechanistic understanding of ARDS that would lead to new therapies. ARDS is characterized by a prothrombotic state and activation of the thrombin receptor protease activated receptor 1 (PAR1). PAR1 is perhaps the most important mediator of inflammation and coagulation in ARDS, as it coordinates the interplay between platelets, endothelial cells, and the immune response. However, targeting PAR1 therapeutically has thus far been unsuccessful, highlighting our knowledge gaps in understanding the pleiotropic roles of this critical receptor. The premise of proposal is that PAR1 plays a previously unappreciated role in the lymphatic vasculature in ARDS that offers a novel therapeutic strategy to prevent lung injury. The lymphatic vasculature mediates the inflammatory response of the lung through both fluid drainage and trafficking of immune cells. However, the molecular pathways that drive these functions have not been fully uncovered. Lymphatics have specialized endothelial cell junctions that mediate fluid and cell uptake into the vessel lumen. Loss of these permeable ‘button’ junctions impairs lymphatic function by preventing the drainage and cell trafficking function of these vessels. Using mouse models, we have found that PAR1 is necessary for button junction formation during lung injury. Lymphatic-specific loss of PAR1 leads to immune cell accumulation and worse lung injury, which our studies suggest is due to loss of button junctions that promote lymphatic function. These data point to a previously unknown role of PAR1 in lung injury that improves lymphatic drainage and promotes resolution of inflammation. In this proposal, we will test the hypothesis that PAR1 is necessary for lymphatic buttons and function (Aim 1), that thrombin-mediated PAR1 signaling in lymphatics is protective during lung injury due to its role in promoting lymphatic buttons and drainage (Aim 2), and that agonists of PAR1 that promote beneficial PAR1 signaling in lymphatics while persevering blood vessel function are a novel therapeutic strategy for ARDS (Aim 3). When completed these studies will result in an entirely new paradigm for the pathogenesis of ARDS by uncovering a link between PAR1, lymphatic function, and the inflammatory response, leading to a novel therapeutic strategy for this devastating disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $750,280 )
2026	2026	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	575 LEXINGTON AVE FL 9	NEW YORK	NY	10022	NEW YORK	USA	Lung Diseases Research	000	2	7/29/2026	NON-COMPETING CONTINUATION	$750,280
														Subtotal = $750,280

Issue Date FY: 2025 ( Subtotal = $791,503 )
2025	2025	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	575 LEXINGTON AVE FL 9	NEW YORK	NY	10022	NEW YORK	USA	Lung Diseases Research	000	1	9/9/2025	NEW	$791,503
														Subtotal = $791,503

Grand Total All Awards = $1,541,783

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identifying Novel Roles and the Therapeutic Potential of the Thrombin Receptor Protease Activated Receptor-1 (PAR1) in Lung Lymphatic Function and Acute Respiratory Distress Syndrome

Award Number: R01HL179084

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer